ADV-101
Oncology (e.g., Esophageal Cancer)
Phase 1Active
Key Facts
About Advesya
Advesya is a private, clinical-stage biotech leveraging a novel target, IL-1RAP, to develop therapies for cancer and autoimmune diseases. Founded in 2020 as a spin-out from the French Blood Institute (EFS), the company has rapidly advanced two core programs: an ADC (ADV-101) and a CAR T-cell therapy (CCTx-001). Backed by investor Jeito and led by an experienced team, Advesya aims to address critical unmet medical needs by inhibiting a key pathway in chronic inflammation and oncology.
View full company profile